Cargando…
Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
In patients hospitalized with COVID-19 pneumonia, both tocilizumab and baricitinib have been shown to have clinical benefit compared with placebo. To date, there are few data comparing the two treatments, and their relative benefits and harms are unknown. This study aims to evaluate the effectivenes...
Autores principales: | Roddy, John, Wells, Daniel, Schenck, Katharine, Santosh, Shrihari, Santosh, Sadashiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243240/ https://www.ncbi.nlm.nih.gov/pubmed/35783551 http://dx.doi.org/10.1097/CCE.0000000000000702 |
Ejemplares similares
-
Effect of Very Low-Dose Hydrocortisone on Shock Reversal in Patients With Septic Shock
por: Sbertoli, Robert, et al.
Publicado: (2020) -
Hypoxemia Trajectory of Non-COVID-19 Acute Respiratory Distress Syndrome Patients. An Observational Study Focusing on Hypoxemia Resolver Status
por: Toal, Connor M., et al.
Publicado: (2023) -
Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls
por: Mert, Ali, et al.
Publicado: (2021) -
Pulse Methylprednisolone Versus Dexamethasone in COVID-19: A Multicenter Cohort Study
por: Watanabe, Atsuyuki, et al.
Publicado: (2023) -
Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019
por: DeGrado, Jeremy R., et al.
Publicado: (2020)